Wydanie 1/2019
str. 51 - 54
Zastosowanie bewacyzumabu w leczeniu cukrzycowej choroby oczu
Bevacizumab Use in the Treatment of Diabetic Eye Disease
Aleksandra Kokoszka, Anna Babik, Agnieszka Filemonowicz-Skoczek, Bożena Romanowska-Dixon
Oddział Kliniczny Okulistyki i Onkologii Okulistycznej Szpitala Uniwersyteckiego w Krakowie
Kierownik: prof. dr hab. n. med. Bożena Romanowska-Dixon
Summary: Diabetic retinopathy is one the most common and most serious ophthalmologic complications of diabetes, that is called the diabetic eye disease.
It is the most common cause of visual loss among the working population.
In advanced diabetic retinopathy diabetic macular edema, neovascular glaucoma, tractional retinal detachment may develop. Bleeding to the vitreous or/ and in to the anterior chamber may also occur. In diabetic eye disease treatment consis of the laser coagulation of the retina, surgical treatment, and injections of the anti-vascular endothelial growth factor. One of the most common anti-vascular endothelial growth factor drugs is bevacizumab. Bevacizumab use in the treatment of diabetic eye disease is described in the paper.
Słowa kluczowe: bewacyzumab, retinopatia cukrzycowa, jaskra neowaskularna, cukrzycowy obrzęk plamki, cukrzycowa choroba oczu, terapia anty-VEGF.
Keywords: bevacizumab, diabetic retinopathy, neovascular glaucoma, diabetic macular edema, diabetic eye disease, anti-VEGF therapy.